In 2017, Gavressa et al. found that the p53 mediated sensitivity of breast cancer cells to chemotherapeutic agents appears to be driven mostly by pRB, and that using agents that enhance RB phosphorylation might possibly increase the chemosensitivity of breast cancer cells. This evidence concerns the gene TP53 and breast carcinoma.